CMND
Clearmind Medicine Inc.
$3.14
-6.82%
$3.2M
No data for this timeframe.
Vol
Market Cap$3.2M
Cap SizeNano Cap
Inst. Holders4 funds
Inst. Value$28.9K
Insider Activity1B / 2S
Insider Net $$295.6K
Reddit Sentiment83° Bullish
SEC Reports20
Press Releases12
Recent Activity
Jun 16, 2026
SEC
Clearmind Medicine announced completion of dosing for all 24 participants in Part A of its Phase I/II clinical trial for
6-K — Impact 4/10
Jun 16, 2026
other
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
Vancouver, Canada, June 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearm
Jun 12, 2026
SEC
HRT Financial LP filed a Form 3 initial statement of beneficial ownership of securities in Clearmind Medicine Inc. (CMND
3 — Impact 2/10
Jun 12, 2026
Insider
HRT FINANCIAL LP sold 2,102 shares
10%+ Owner @ $3.36 ($7.1K)
Jun 11, 2026
Insider
HRT FINANCIAL LP sold 225,191 shares
10%+ Owner @ $0.1230 ($27.7K)
Jun 10, 2026
Insider
HRT FINANCIAL LP bought 2,159,052 shares
10%+ Owner @ $0.1530 ($330.3K)
Jun 5, 2026
Press
Clearmind Medicine announced a live webinar on June 10, 2026, featuring investigators from Yale and Johns Hopkins to dis
Impact 2/10
May 29, 2026
SEC
Clearmind Medicine announced the publication of a Japanese patent application for its MEAI-based depression treatment, e
6-K — Impact 3/10
Latest Reports
NEUTRAL
6-K
4/10
Clearmind Medicine announced completion of dosing for all 24 participants in Part A of its Phase I/II clinical trial for
Jun 16, 2026
NEUTRAL
3
2/10
HRT Financial LP filed a Form 3 initial statement of beneficial ownership of securities in Clearmind Medicine Inc. (CMND
Jun 12, 2026
NEUTRAL
Press
2/10
Clearmind Medicine announced a live webinar on June 10, 2026, featuring investigators from Yale and Johns Hopkins to dis
Jun 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24.9K | — |
| MORGAN STANLEY | $2.6K | — |
| ROYAL BANK OF CANADA | $1.0K | — |
| NATIONAL BANK OF CANADA | $387.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 12, 2026 | HRT FINANCIAL | SELL | $7.1K |
| Jun 11, 2026 | HRT FINANCIAL | SELL | $27.7K |
| Jun 10, 2026 | HRT FINANCIAL | BUY | $330.3K |
Reddit Sentiment
83°
Bullish
Bearish
Neutral
Bullish
4 institutional holders with $28.9K total value (27,804 shares) as of 2025-Q3. Top holders: SUSQUEHANNA, MORGAN, ROYAL.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 24,292 | $24.9K | 86.1% | — |
| 2 | MORGAN STANLEY | 2,564 | $2.6K | 9.1% | — |
| 3 | ROYAL BANK OF CANADA | 569 | $1.0K | 3.5% | — |
| 4 | NATIONAL BANK OF CANADA /FI/ | 379 | $387.00 | 1.3% | — |
1 unique insiders with 3 transactions. Net insider value: $295.6K ($330.3K bought, $34.8K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | HRT FINANCIAL LP | 10%+ Owner | SELL | 2,102 | $3.36 | $7.1K |
| Jun 11, 2026 | HRT FINANCIAL LP | 10%+ Owner | SELL | 225,191 | $0.1230 | $27.7K |
| Jun 10, 2026 | HRT FINANCIAL LP | 10%+ Owner | BUY | 2,159,052 | $0.1530 | $330.3K |
20 SEC filing reports analyzed. Sentiment: 3 bullish, 6 bearish, 2 mixed, 9 neutral. Avg impact: 5.0/10.
NEUTRAL
6-K
4/10
Clearmind Medicine announced completion of dosing for all 24 participants in Part A of its Phase I/I
Jun 16, 2026
NEUTRAL
3
2/10
HRT Financial LP filed a Form 3 initial statement of beneficial ownership of securities in Clearmind
Jun 12, 2026
NEUTRAL
6-K
3/10
Clearmind Medicine announced the publication of a Japanese patent application for its MEAI-based dep
May 29, 2026
NEUTRAL
6-K
4/10
Clearmind Medicine announced that the Johns Hopkins IRB approved advancing its Phase I/II CMND-100 t
May 26, 2026
BEARISH
6-K
6/10
Clearmind Medicine entered into a conversion agreement for $600,000 of convertible notes at $0.30 pe
May 19, 2026
NEUTRAL
6-K
4/10
Clearmind Medicine announced a 1-for-10 reverse share split effective May 21, 2026, intended to rega
May 19, 2026
BEARISH
6-K
7/10
Clearmind Medicine announced the issuance of $600,000 in convertible promissory notes at a 10% disco
May 18, 2026
NEUTRAL
6-K
4/10
Clearmind Medicine announced a preclinical research agreement with Hebrew University to study its le
May 18, 2026
NEUTRAL
6-K
3/10
Clearmind Medicine announced it has dosed two additional participants in the fourth cohort of its Ph
May 12, 2026
BEARISH
EFFECT
6/10
Clearmind Medicine's registration statement on Form F-3 (File No. 333-295455) was declared effective
May 8, 2026
NEUTRAL
6-K
3/10
Clearmind Medicine announced the filing of a European patent application for novel psychedelic compo
May 5, 2026
MIXED
6-K
5/10
Clearmind Medicine announced it is evaluating its lead candidate CMND-100 (MEAI) for potential FDA B
Apr 27, 2026
BEARISH
6-K
6/10
Clearmind Medicine Inc. (CMND) announced the conversion of $2,680,029.60 in convertible promissory n
Apr 21, 2026
BEARISH
6-K
6/10
Clearmind Medicine Inc. (CMND) announced a $2.7 million financing through the issuance of convertibl
Apr 20, 2026
NEUTRAL
6-K
3/10
Clearmind Medicine issued a press release via Form 6-K welcoming President Trump's April 18, 2026, e
Apr 20, 2026
BULLISH
6-K
7/10
Clearmind Medicine announced that its independent Data and Safety Monitoring Board (DSMB) issued a p
Apr 15, 2026
BEARISH
6-K
6/10
Clearmind Medicine Inc. announced that investors converted $875,000 of convertible notes into common
Apr 15, 2026
MIXED
6-K
6/10
Clearmind Medicine Inc. announced the issuance of $1.75 million in convertible promissory notes at a
Apr 14, 2026
BULLISH
6-K
7/10
Clearmind Medicine announced that its drug candidate CMND-100 met the primary safety and tolerabilit
Apr 14, 2026
BULLISH
6-K
7/10
Clearmind Medicine announced the successful completion of treatment and follow-up for 18 participant
Mar 30, 2026
NEUTRAL
2/10
Clearmind Medicine announced a live webinar on June 10, 2026, featuring investigators from Yale and
Jun 5, 2026
NEUTRAL
3/10
Clearmind Medicine announced a Japanese patent application for its MEAI-based depression treatment,
May 29, 2026
NEUTRAL
4/10
Clearmind Medicine announced that the Johns Hopkins Medicine IRB has approved its Phase I/II trial o
May 26, 2026
BEARISH
5/10
Clearmind Medicine announces a 1-for-10 reverse stock split effective May 21, 2026, to regain compli
May 19, 2026
NEUTRAL
2/10
Clearmind Medicine's CEO participated in an invite-only federal policy summit at the National Press
May 15, 2026
NEUTRAL
2/10
Clearmind Medicine announced a live webinar on June 10, 2026, to discuss early clinical data from it
May 11, 2026
NEUTRAL
3/10
Clearmind Medicine (CMND) issued a press release commending a presidential executive order that prio
Apr 20, 2026
BULLISH
8/10
Clearmind Medicine announced that its drug candidate CMND-100 met the primary safety and tolerabilit
Apr 20, 2026
BULLISH
7/10
Clearmind Medicine announced that its drug candidate CMND-100 met the primary safety and tolerabilit
Apr 14, 2026
NEUTRAL
4/10
Clearmind Medicine announced the filing of a patent application in India for next-generation, non-ha
Mar 27, 2026
NEUTRAL
4/10
Clearmind Medicine announced the publication of six patents in Hong Kong covering proprietary combin
Mar 17, 2026
NEUTRAL
4/10
Clearmind Medicine announced the continuation of participant enrollment in the third cohort of its F
Mar 11, 2026
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
83°
Bullish
Bearish
Neutral
Bullish
8 mentions
8 bullish
0 bearish
8 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Clearmind Medicine Inc. (NASDAQ:CMND) mentioned before stock info the of day ibogaine stock.
▲ 1
💬 1
⚡ 0.5
CMND anyone?
▲ 1
💬 1
⚡ 0.5
Jun 16, 2026
other
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
Vancouver, Canada, June 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech c
Jun 5, 2026
announcement
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar <pre>Yale and Johns Hopkins Researchers to Present Earl
May 29, 2026
announcement
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
<p>Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biot
May 26, 2026
announcement
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
<p>Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biot
May 20, 2026
short_volume
Short Volume: CMND — 62.4% short (0.5M / 0.7M)
Short: 460,354 | Exempt: 69,092 | TRF Vol: 737,299 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
May 19, 2026
announcement
Clearmind Medicine Announces 1-for-10 Reverse Share Split
<p align="justify">Vancouver, Canada, May 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a cli
May 19, 2026
ftd
FTD: CMND — 4,214,780 shares ($1.6M) failed to deliver
Settlement: 20260519, Price: $0.38, FTD Value: $1,601,616.4, CLEARMIND MEDICINE INC COM NO
May 18, 2026
other
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
<p>Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biot
May 18, 2026
short_volume
Short Volume: CMND — 57.2% short (6.2M / 10.8M)
Short: 6,166,493 | Exempt: 863,987 | TRF Vol: 10,771,673 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
announcement
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
<p><i>Federal Officials, Researchers, Clinicians and Biopharma Leadership Convene</i><i>d</i><i> by Psychedelic Medicine Coalition at the National Pre
May 12, 2026
other
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
<p>Vancouver, Canada, May 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biote
May 11, 2026
announcement
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
<p align="center"><span><b>Registration Now Open </b></span><span dir="RTL"><b>-</b></span><span> </span><a href="https://www.globenewswire.com/Tracke
May 5, 2026
other
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
<p>Vancouver, Canada, May 05, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biot
Apr 27, 2026
other
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
<p><i>Positive clinical results from Alcohol Use Disorder</i><i> clinical</i><i> trial </i><i>may </i><i>strengthen potential for </i><i>eligibility f
Apr 21, 2026
short_interest
FTD: CMND — 3,468,520 shares ($4.0M) failed to deliver
Settlement: 20260421, Price: $1.14, FTD Value: $3,954,112.8, CLEARMIND MEDICINE INC COM NO